First slide
Sureseq Logo

Product summary

  • Technology NGS
  • Application Haematology, Solid tumour
  • Gene Targets 1 - 210+
  • Aberration Types SNV, indel, ITD, PTD, CNV, translocation
  • Product Code Various
  • Regulatory Status For research use only; not for diagnostic procedures.


Introduction - Tired of paying to sequence genes you’re not interested in? Then don’t!

SureSeq myPanel™ is a regularly updated, expert-curated library of pre-optimised cancer panel content for you to select from. Simply mix and match the gene, exonic or intronic content you need to create an NGS cancer panel that meets your exact requirements.

Our unique panel design coupled with hybridisation-based enrichment offers unparalleled coverage completeness and uniformity. This allows the accurate detection of difficult to sequence, low-frequency variants and minimises the requirement for supplementary fill-in with Sanger sequencing.

Getting started with your SureSeq myPanel NGS Custom Panel could not be simpler, find out more in this video…

  • Hybridisation-based panel delivering unparalleled coverage uniformity — detect low-frequency variants consistently with confidence and minimise the requirement for supplementary fill-in with Sanger sequencing
  • Pre-optimised panels that meet your technical requirements and work with your samples (including FFPE tissue) — no more laborious in-house optimisation, decreasing assay development time
  • Bespoke panel content — sequence only what’s relevant for your cancer research, increase throughput and save on sequencing reagents
  • Panel content designed with experts and from current literature to target all relevant regions including intronic and splice sites — get the most comprehensive insight into disease-driving mutations

Gene targets

Select a gene to view exon coverage examples:
Show more

* Exon examples not yet available


Excellent coverage of “difficult” genes

Mutations in the CEBPA gene are among the most common molecular alterations in AML and bear important significance. Sequencing of the CEBPA gene is often hampered by a repetitive nucleotide sequence and a high GC-rich content, which can lead to technical challenges in assay design, requiring a supplementary fill-in with Sanger sequencing. OGT’s expert bait design overcomes these issues, offer a high level of uniformity coverage for a notoriously difficult gene to sequence.

Don’t miss critical variants

The CALR gene is commonly mutated in various myeloproliferative neoplasms (MPNs). It is critical to identify key CALR indels (types 1 and 2 causing a frameshift) as well as increasingly recognised point mutations in this gene. OGT’s expert bait design offers excellent coverage uniformity across low-complexity regions with low nucleotide diversity (such as CALR exon 9), compared to other commercially available bait designs, which suffer from a considerable dip in coverage.

BCR-ABL fusion gene

The BCR-ABL gene fusion is formed following a balanced translocation of chromosome 9 and 22, generating the Philadelphia chromosome, a hallmark of CML. Combine SNV and indel detection with BCR-ABL translocation content and replace multiple assays with a single streamlined NGS workflow for a more comprehensive picture of all your samples.

Sophisticated bait design strategies allowing reliable KMT2A-PTD detection

Partial tandem duplications in KMT2A (MLL), frequently observed in AML, are notoriously difficult to detect due to their size, often spanning multiple exons. With OGT’s expertise in hybridisation-based panel design, your SureSeq myPanel offers robust detection of all sizes of KMT2A-PTDs, alleviating the burden of running multiple assays (Figure 5).

SureSeq myPanel NGS Custom Cancer Panels workflow


  1. Drexler HG, Dirks W, MacLeod RAF, Quentmeier H, Steube K, Uphoff CC, editors. DSMZ Catalogue of Human and Animal Cell Lines, 6th ed. Braunschweig, Germany: DSMZ, 1997.
View all products

NGS resources & support